Recently, Shenzhen ROBO Medical Technology Co., Ltd., the pioneer globally in obtaining approval for a digestive endoscopic surgical robot, declared the successful completion of a funding round amounting to tens of millions of yuan. This funding initiative was spearheaded by Tsinghua Waterwood Venture Capital, with contributions from Boyue Tiancheng. Additionally, Seiche Consulting provided exclusive long-term financial advisory services. The capital raised will be primarily allocated towards the nationwide clinical promotion of the flagship product, EndoFaster®, the R&D of the next-gen product, EndoDreams, the establishment of an intelligent production facility, supply chain enhancement, as well as international market certification and hospital entry initiatives.

The National Healthcare Security Administration has issued pertinent guidelines, establishing a unified pricing framework for surgical robots. This framework bases pricing on clinical value, without differentiating between domestic and international brands, thereby creating a fair competitive environment for domestic innovative companies.

As the world's inaugural and currently sole approved entity for digestive endoscopic surgical robots in China, ROBO Medical's EndoFaster® system has exhibited outstanding performance in ESD procedures. It has gained product access in all 31 provincial-level administrative regions nationwide. Approved in March 2025, the system boasts an external flexible robotic arm design that precisely elevates tissues, consistently reveals the surgical field, mitigates surgical risks, shortens the learning curve for medical professionals, and enhances technological accessibility.

Recently, EndoFaster® made its international debut at academic conferences, garnering acclaim. Notably, Professor Hisao Tajiri, Honorary Chairman of the Japan Gastroenterological Endoscopy Society, lauded it as a paragon of next-generation endoscopic technology at the JGES conference.

Presently, the global digestive endoscopic surgical robot sector is witnessing swift expansion, with industry pundits forecasting explosive market growth. Capitalizing on its first-mover advantage, technological prowess, and supportive policy landscape, ROBO Medical is well-positioned to claim a dominant market share. Both Tsinghua Waterwood Venture Capital and Seiche Consulting have expressed confidence in its growth trajectory.